I.v

Abnormal lung function/pulmonary physiology (PFTs) without necessarily imaging or clinical evidence

(Fr: Sd restrictif ou altération de la diffusion isolés). Change in static or dynamic volumes or flows, diffusion for CO, compliance, ABG or distribution of ventilation. Pulmonary function tests (PFTs) may show a restrictive lung function defect or a lowtrending diffusing capacity for CO without necessarily the presence of clinical symptoms or definite changes on imaging including HRCT. Changes in PFT may develop concomitant with the administration of the causal drug or drugs, or they are noted as a persistent late finding upon termination of treatment or as a slowly progressive drift that needs be followed-up. These findings may reflect incipient or rampant subclinical ILD or pulmonary fibrosis, bronchiolitis obliterans, pulmonary hypertension or pleural fibrosis

Last update : 01/01/1970
 

Causative drugs

28

Bleomycin

I.a I - Interstitial/parenchymal lung disease
I.a - Pneumonitis (ILD), acute and/or severe (may cause ARDS) I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD) I.c I - Interstitial/parenchymal lung disease
I.c - Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia) I.d I - Interstitial/parenchymal lung disease
I.d - Organizing pneumonia pattern (an area or areas of consolidation on imaging) I.f I - Interstitial/parenchymal lung disease
I.f - Acute fibrinous organizing pneumonia (AFOP) I.g I - Interstitial/parenchymal lung disease
I.g - Pulmonary fibrosis I.k I - Interstitial/parenchymal lung disease
I.k - Lung nodule or nodules I.l I - Interstitial/parenchymal lung disease
I.l - Diffuse alveolar damage (DAD) (see alsoo under IIb and XVf) I.p I - Interstitial/parenchymal lung disease
I.p - Fatal pneumonitis (ILD) I.v I - Interstitial/parenchymal lung disease
I.v - Abnormal lung function/pulmonary physiology (PFTs) without necessarily imaging or clinical evidence I.w I - Interstitial/parenchymal lung disease
I.w - Rapidly progressive ILD/pulmonary fibrosis (Hamman-Rich syndrome) II.b II - Pulmonary edema - Acute lung injury - ARDS
II.b - ARDS - Acute lung injury II.u II - Pulmonary edema - Acute lung injury - ARDS
II.u - Acute respiratory failure (e.g. from ARDS, ILD, PIE, OP, pulmonary edema or bronchospasm) requiring ECMO V.f V - Pleural and/or pericardial involvement
V.f - Pneumothorax V.p V - Pleural and/or pericardial involvement
V.p - Pleuroparenchymal fibroelastosis (PPFE) V.z V - Pleural and/or pericardial involvement
V.z - Pneumothorax (associated or secondary to drug-induced ILD) VI.c VI - Pulmonary vasculopathies
VI.c - Pulmonary veno-occlusive disease VI.f VI - Pulmonary vasculopathies
VI.f - Hemolytic and uremic syndrome (HUS). See also under Xaf VII.e VII - Mediastinal involvement
VII.e - Granulomatous mediastinal lymphadenopathy VII.h VII - Mediastinal involvement
VII.h - Pneumomediastinum XI.b XI - Miscellaneous
XI.b - Chest pain (acute or subacute), lone or prominent XI.c XI - Miscellaneous
XI.c - Pleuritic chest pain XV.a XV - Pathology
XV.a - Path: NSIP-cellular pattern (see also Ia, Ib) XV.b XV - Pathology
XV.b - Path: Eosinophilic pneumonia (subacute or acute) (see also Ic) XV.c XV - Pathology
XV.c - Path: Organizing pneumonia (OP/BOOP) pattern (see also Id) XV.d XV - Pathology
XV.d - Path: Acute fibrinous organizing pneumonia (AFOP-pattern) (see also If) XV.f XV - Pathology
XV.f - Path: Diffuse alveolar damage (DAD-pattern) (see also IL) XV.h XV - Pathology
XV.h - Path: NSIP-fibrotic pattern XV.i XV - Pathology
XV.i - Path: Pneumocyte atypia (reactive epithelial cells) (a.k.a. the "Napoleon Hat" sign) XV.j XV - Pathology
XV.j - Path: Pulmonary fibrosis (UIP-pattern) XV.l XV - Pathology
XV.l - Path: Pulmonary fibrosis (not otherwise specified or unclassifiable) XV.ax XV - Pathology
XV.ax - Path: Focal organizing pneumonia XV.be XV - Pathology
XV.be - Path: Interstitial pulmonary edema XV.bf XV - Pathology
XV.bf - Path: Pulmonary necrotizing granuloma or granulomas XVI.a XVI - Imaging
XVI.a - Imaging: Diffuse haze XVI.b XVI - Imaging
XVI.b - Imaging: Ground-glass opacities (GGO) / shadowing XVI.e XVI - Imaging
XVI.e - Imaging: Pulmonary opacities with a subpleural distribution XVI.k XVI - Imaging
XVI.k - Imaging: An area or areas of consolidation XVI.w XVI - Imaging
XVI.w - Imaging: Lung nodule or nodules XVI.ab XVI - Imaging
XVI.ab - Imaging: Cavitating/cavitary lung nodule, mass or nodules (see also Iq, XIs, XIIi, XVIaa and XVIIp) XVI.af XVI - Imaging
XVI.af - Imaging: Lung cysts or bullae (see also XVI ah/bf) XVI.bl XVI - Imaging
XVI.bl - Imaging: An area or areas of avid tracer uptake in the lung/chest on 18F-PET scan XVIII.j XVIII - Distinctive patterns - 'Eye-catchers'
XVIII.j - Eye-catcher: Avid lung uptake on 18F-PET-CT XIX.b XIX - Cytological, biochemical features of/in BAL, pleural fluid or FNA
XIX.b - BAL: An excess proportion of neutrophils XXIV.a XXIV - Veterinary medicine
XXIV.a - Veterinary: Pneumonitis - Interstitial lung disease XXIV.b XXIV - Veterinary medicine
XXIV.b - Veterinary: Pulmonary fibrosis
3

Busulfan

I.a I - Interstitial/parenchymal lung disease
I.a - Pneumonitis (ILD), acute and/or severe (may cause ARDS) I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD) I.d I - Interstitial/parenchymal lung disease
I.d - Organizing pneumonia pattern (an area or areas of consolidation on imaging) I.g I - Interstitial/parenchymal lung disease
I.g - Pulmonary fibrosis I.l I - Interstitial/parenchymal lung disease
I.l - Diffuse alveolar damage (DAD) (see alsoo under IIb and XVf) I.n I - Interstitial/parenchymal lung disease
I.n - Pulmonary alveolar proteinosis (PAP) I.v I - Interstitial/parenchymal lung disease
I.v - Abnormal lung function/pulmonary physiology (PFTs) without necessarily imaging or clinical evidence II.b II - Pulmonary edema - Acute lung injury - ARDS
II.b - ARDS - Acute lung injury XV.a XV - Pathology
XV.a - Path: NSIP-cellular pattern (see also Ia, Ib) XV.c XV - Pathology
XV.c - Path: Organizing pneumonia (OP/BOOP) pattern (see also Id) XV.d XV - Pathology
XV.d - Path: Acute fibrinous organizing pneumonia (AFOP-pattern) (see also If) XV.f XV - Pathology
XV.f - Path: Diffuse alveolar damage (DAD-pattern) (see also IL) XV.h XV - Pathology
XV.h - Path: NSIP-fibrotic pattern XV.i XV - Pathology
XV.i - Path: Pneumocyte atypia (reactive epithelial cells) (a.k.a. the "Napoleon Hat" sign) XV.n XV - Pathology
XV.n - Path: Pulmonary alveolar proteinosis pattern (PAP pattern) XV.bc XV - Pathology
XV.bc - Path: Opportunistic pulmonary infection (see also XVII/XVIIb-d-e) XVI.d XVI - Imaging
XVI.d - Imaging: Alveolar opacities or haze with a batwing or butterfly distribution XVII.f XVII - Infections & related conditions
XVII.f - Tuberculosis, miliary XIX.g XIX - Cytological, biochemical features of/in BAL, pleural fluid or FNA
XIX.g - BAL: Atypical epithelial cells (at times poetically named
1

Chemotherapy, antineoplastic

I.a I - Interstitial/parenchymal lung disease
I.a - Pneumonitis (ILD), acute and/or severe (may cause ARDS) I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD) I.c I - Interstitial/parenchymal lung disease
I.c - Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia) I.d I - Interstitial/parenchymal lung disease
I.d - Organizing pneumonia pattern (an area or areas of consolidation on imaging) I.f I - Interstitial/parenchymal lung disease
I.f - Acute fibrinous organizing pneumonia (AFOP) I.g I - Interstitial/parenchymal lung disease
I.g - Pulmonary fibrosis I.h I - Interstitial/parenchymal lung disease
I.h - Subclinical pulmonary infiltrates/ILD I.k I - Interstitial/parenchymal lung disease
I.k - Lung nodule or nodules I.l I - Interstitial/parenchymal lung disease
I.l - Diffuse alveolar damage (DAD) (see alsoo under IIb and XVf) I.m I - Interstitial/parenchymal lung disease
I.m - ILD with a granulomatous component I.n I - Interstitial/parenchymal lung disease
I.n - Pulmonary alveolar proteinosis (PAP) I.v I - Interstitial/parenchymal lung disease
I.v - Abnormal lung function/pulmonary physiology (PFTs) without necessarily imaging or clinical evidence I.w I - Interstitial/parenchymal lung disease
I.w - Rapidly progressive ILD/pulmonary fibrosis (Hamman-Rich syndrome) I.x I - Interstitial/parenchymal lung disease
I.x - Pleuroparenchymal fibroelastosis (PPFE) I.y I - Interstitial/parenchymal lung disease
I.y - Progression, acceleration or exacerbation of preexisting ILD/fibrosis I.aa I - Interstitial/parenchymal lung disease
I.aa - Delayed ILD, -pneumonitis, -fibrosis I.ad I - Interstitial/parenchymal lung disease
I.ad - Radiation recall pneumonitis I.au I - Interstitial/parenchymal lung disease
I.au - The chemotherapy lung II.a II - Pulmonary edema - Acute lung injury - ARDS
II.a - Pulmonary edema, noncardiogenic (NCPE) II.b II - Pulmonary edema - Acute lung injury - ARDS
II.b - ARDS - Acute lung injury II.c II - Pulmonary edema - Acute lung injury - ARDS
II.c - ARDS and the hemolytic-uremic syndrome (HUS) II.d II - Pulmonary edema - Acute lung injury - ARDS
II.d - Pulmonary edema, cardiogenic III.a III - Pulmonary/alveolar./airway hemorrhage/bleeding
III.a - Alveolar hemorrhage (AH), diffuse AH (DAH) IV.a IV - Airway involvement
IV.a - Bronchospasm - Wheezing - Asthma IV.k IV - Airway involvement
IV.k - Bronchiectasis V.a V - Pleural and/or pericardial involvement
V.a - Pleural effusion (uni- or bilateral) (can accompany DI-LDs) V.f V - Pleural and/or pericardial involvement
V.f - Pneumothorax V.ab V - Pleural and/or pericardial involvement
V.ab - Pneumothorax, bilateral VI.b VI - Pulmonary vasculopathies
VI.b - Pulmonary arterial hypertension VI.c VI - Pulmonary vasculopathies
VI.c - Pulmonary veno-occlusive disease VI.f VI - Pulmonary vasculopathies
VI.f - Hemolytic and uremic syndrome (HUS). See also under Xaf VII.a VII - Mediastinal involvement
VII.a - Lymphadenopathy (intrathoracic) VII.h VII - Mediastinal involvement
VII.h - Pneumomediastinum VIII.a VIII - Central-large-upper airway (incl. pharyngeal-nasal) involvement
VIII.a - Angioedema (may cause UAO, asphyxia and death) VIII.t VIII - Central-large-upper airway (incl. pharyngeal-nasal) involvement
VIII.t - Vocal cord paresis/paralysis IX.f IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.f - Hiccup IX.j IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.j - Phrenic nerve injury - Hemi- or bilateral diaphragmatic paralysis IX.o IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.o - Pneumorachis X.c X - Systemic/Distant conditions, syndromes and reactions
X.c - Capillary leak syndrome (CLS) X.d X - Systemic/Distant conditions, syndromes and reactions
X.d - Lupus - Lupus syndrome (see also Vd) X.f X - Systemic/Distant conditions, syndromes and reactions
X.f - Anaphylaxis-Anaphylactoid reaction (can be fatal) X.g X - Systemic/Distant conditions, syndromes and reactions
X.g - Hypersensitivity reaction (may manifest with fever and/or skin, throat or airway involvement) X.k X - Systemic/Distant conditions, syndromes and reactions
X.k - Sarcoid-like granulomatosis (endo-/extrathoracic) X.n X - Systemic/Distant conditions, syndromes and reactions
X.n - Tumor lysis syndrome (TLS) XI.b XI - Miscellaneous
XI.b - Chest pain (acute or subacute), lone or prominent XI.n XI - Miscellaneous
XI.n - Neutropenia, agranulocytosis (w/wo infection/sepsis) XI.w XI - Miscellaneous
XI.w - Cavitation/necrosis of lung tumor or metastases XII.a XII - Cardiovascular involvement / toxicity
XII.a - Left or biventricular dysfunction/failure XII.b XII - Cardiovascular involvement / toxicity
XII.b - Valvular heart disease and/or dysfunction XII.c XII - Cardiovascular involvement / toxicity
XII.c - Pericardial effusion (w/wo tamponade) XII.e XII - Cardiovascular involvement / toxicity
XII.e - Takotsubo (stress) cardiomyopathy XII.f XII - Cardiovascular involvement / toxicity
XII.f - Cardiomyopathy (acute, subacute, chronic) XII.g XII - Cardiovascular involvement / toxicity
XII.g - Coronary artery disease (acute) - Myocardial ischemia/infarction XII.l XII - Cardiovascular involvement / toxicity
XII.l - Cardiac arrhythmias or dysrhythmias (AF, VT, VF, TdP) XII.s XII - Cardiovascular involvement / toxicity
XII.s - Heart block (bundle branch- or AV-) XII.ai XII - Cardiovascular involvement / toxicity
XII.ai - Cardiotoxicity XII.bv XII - Cardiovascular involvement / toxicity
XII.bv - Atrial fibrillation XIII.a XIII - Neoplastic conditions
XIII.a - Lung cancer XIII.b XIII - Neoplastic conditions
XIII.b - Lymphoproliferative disease (pulmonary, endobronchial, endothoracic) XIII.d XIII - Neoplastic conditions
XIII.d - Malignant mesothelioma (pleural, pericardial) XV.c XV - Pathology
XV.c - Path: Organizing pneumonia (OP/BOOP) pattern (see also Id) XV.d XV - Pathology
XV.d - Path: Acute fibrinous organizing pneumonia (AFOP-pattern) (see also If) XV.f XV - Pathology
XV.f - Path: Diffuse alveolar damage (DAD-pattern) (see also IL) XV.i XV - Pathology
XV.i - Path: Pneumocyte atypia (reactive epithelial cells) (a.k.a. the "Napoleon Hat" sign) XV.l XV - Pathology
XV.l - Path: Pulmonary fibrosis (not otherwise specified or unclassifiable) XV.ak XV - Pathology
XV.ak - Path: Pulmonary veno-occlusive disease (PVOD) XV.am XV - Pathology
XV.am - Path: Thrombosis in pulmonary arterioles/venules XV.ba XV - Pathology
XV.ba - Path: Granulomatous lymphadenopathy XVI.ab XVI - Imaging
XVI.ab - Imaging: Cavitating/cavitary lung nodule, mass or nodules (see also Iq, XIs, XIIi, XVIaa and XVIIp) XVI.af XVI - Imaging
XVI.af - Imaging: Lung cysts or bullae (see also XVI ah/bf) XVI.bf XVI - Imaging
XVI.bf - Imaging: Tumoral cavitation XVI.bl XVI - Imaging
XVI.bl - Imaging: An area or areas of avid tracer uptake in the lung/chest on 18F-PET scan XVI.bw XVI - Imaging
XVI.bw - Imaging: Air or an air crescent around lung tumor or metastase(s) XVII.b XVII - Infections & related conditions
XVII.b - Opportunistic pulmonary/systemic infections XVII.c XVII - Infections & related conditions
XVII.c - Aspergillosis, pulmonary (invasive, allergic [ABPA], or mycetoma) XVII.e XVII - Infections & related conditions
XVII.e - Pneumocystis jiroveci pneumonia XVII.g XVII - Infections & related conditions
XVII.g - Tuberculosis (pulmonary, pulmonary, extrapulmonary or disseminated). Reactivation or de novo XVII.j XVII - Infections & related conditions
XVII.j - Mucormycosis (pulmonary, tracheobronchial or systemic) XVII.r XVII - Infections & related conditions
XVII.r - Fungal infection (pulmonary/extrapulmonary) XVII.af XVII - Infections & related conditions
XVII.af - Reactivation of a prior pulmonary infection (TB, melioidosis) XIX.g XIX - Cytological, biochemical features of/in BAL, pleural fluid or FNA
XIX.g - BAL: Atypical epithelial cells (at times poetically named
4

E-cigarette - E-vaporizers - ENDS - Vaping - Dabbing

I.a I - Interstitial/parenchymal lung disease
I.a - Pneumonitis (ILD), acute and/or severe (may cause ARDS) I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD) I.c I - Interstitial/parenchymal lung disease
I.c - Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia) I.d I - Interstitial/parenchymal lung disease
I.d - Organizing pneumonia pattern (an area or areas of consolidation on imaging) I.e I - Interstitial/parenchymal lung disease
I.e - Acute eosinophilic pneumonia (AEP) I.j I - Interstitial/parenchymal lung disease
I.j - Exogenous lipoid pneumonia (subacute, acute) I.m I - Interstitial/parenchymal lung disease
I.m - ILD with a granulomatous component I.u I - Interstitial/parenchymal lung disease
I.u - Relapsing or migrating pneumonitis/pneumonia (see also Id) I.v I - Interstitial/parenchymal lung disease
I.v - Abnormal lung function/pulmonary physiology (PFTs) without necessarily imaging or clinical evidence I.aw I - Interstitial/parenchymal lung disease
I.aw - Persistent reduction in diffusing capacity for CO upon resolution of the adverse effect I.ax I - Interstitial/parenchymal lung disease
I.ax - Chronic pneumonitis II.b II - Pulmonary edema - Acute lung injury - ARDS
II.b - ARDS - Acute lung injury II.u II - Pulmonary edema - Acute lung injury - ARDS
II.u - Acute respiratory failure (e.g. from ARDS, ILD, PIE, OP, pulmonary edema or bronchospasm) requiring ECMO III.a III - Pulmonary/alveolar./airway hemorrhage/bleeding
III.a - Alveolar hemorrhage (AH), diffuse AH (DAH) III.c III - Pulmonary/alveolar./airway hemorrhage/bleeding
III.c - Hemoptysis III.m III - Pulmonary/alveolar./airway hemorrhage/bleeding
III.m - Coagulopathy IV.a IV - Airway involvement
IV.a - Bronchospasm - Wheezing - Asthma IV.d IV - Airway involvement
IV.d - Cough (lone) IV.f IV - Airway involvement
IV.f - Severe or catastrophic bronchospasm or asthma attack (can be fatal) IV.k IV - Airway involvement
IV.k - Bronchiectasis IV.n IV - Airway involvement
IV.n - Obstructive airway dysfunction (see also IVc, XVx) IV.p IV - Airway involvement
IV.p - Thermal, chemical or caustic airway injury IV.q IV - Airway involvement
IV.q - Reactive airway dysfunction syndrome (RADS) IV.t IV - Airway involvement
IV.t - Sptutum production - Bronchorrhea - 'Bronchitis' IV.v IV - Airway involvement
IV.v - Deterioration/exacerbation of preexisting asthma or COPD IV.ad IV - Airway involvement
IV.ad - Large airway inflammation - Tracheitis (w/wo tissue eosinophilia) V.a V - Pleural and/or pericardial involvement
V.a - Pleural effusion (uni- or bilateral) (can accompany DI-LDs) V.f V - Pleural and/or pericardial involvement
V.f - Pneumothorax VII.a VII - Mediastinal involvement
VII.a - Lymphadenopathy (intrathoracic) VII.e VII - Mediastinal involvement
VII.e - Granulomatous mediastinal lymphadenopathy VII.h VII - Mediastinal involvement
VII.h - Pneumomediastinum VIII.d VIII - Central-large-upper airway (incl. pharyngeal-nasal) involvement
VIII.d - Thermal (burns, frostbite), chemical or caustic injury on the face, mouth, tongue, pharynx or upper airway VIII.al VIII - Central-large-upper airway (incl. pharyngeal-nasal) involvement
VIII.al - Epiglottitis VIII.an VIII - Central-large-upper airway (incl. pharyngeal-nasal) involvement
VIII.an - Facial/labial/buccal/oral/dental trauma VIII.ap VIII - Central-large-upper airway (incl. pharyngeal-nasal) involvement
VIII.ap - Airway foreign body VIII.at VIII - Central-large-upper airway (incl. pharyngeal-nasal) involvement
VIII.at - Gross tracheal inflammation on endoscopy IX.h IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.h - Dyspnea, unexplained otherwise IX.af IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.af - Seizures X.b X - Systemic/Distant conditions, syndromes and reactions
X.b - Antiphospholipid antibodies w/wo the APL syndrome X.k X - Systemic/Distant conditions, syndromes and reactions
X.k - Sarcoid-like granulomatosis (endo-/extrathoracic) X.aq X - Systemic/Distant conditions, syndromes and reactions
X.aq - Relapse or flare of preexisting ulcerative colitis XI.b XI - Miscellaneous
XI.b - Chest pain (acute or subacute), lone or prominent XI.r XI - Miscellaneous
XI.r - Death following exposure or poisoning XI.ac XI - Miscellaneous
XI.ac - Thermal skin/dermal injury XI.ay XI - Miscellaneous
XI.ay - Chest tightness XI.bc XI - Miscellaneous
XI.bc - Polycythemia XI.bd XI - Miscellaneous
XI.bd - Nicotine poisoning XI.be XI - Miscellaneous
XI.be - Burns XII.a XII - Cardiovascular involvement / toxicity
XII.a - Left or biventricular dysfunction/failure XII.l XII - Cardiovascular involvement / toxicity
XII.l - Cardiac arrhythmias or dysrhythmias (AF, VT, VF, TdP) XII.ag XII - Cardiovascular involvement / toxicity
XII.ag - Bradycardia XIV.a XIV - Hemoglobinopathies - Abnormal hemoglobin states (acquired)
XIV.a - Methemoglobinemia XV.c XV - Pathology
XV.c - Path: Organizing pneumonia (OP/BOOP) pattern (see also Id) XV.d XV - Pathology
XV.d - Path: Acute fibrinous organizing pneumonia (AFOP-pattern) (see also If) XV.e XV - Pathology
XV.e - Path: ILD with a granulomatous component (see also Im) XV.f XV - Pathology
XV.f - Path: Diffuse alveolar damage (DAD-pattern) (see also IL) XV.g XV - Pathology
XV.g - Path: Alveolar hemorrhage (see also IIIa) XV.p XV - Pathology
XV.p - Path: Exogenous lipoid pneumonia XV.x XV - Pathology
XV.x - Path: Acute/subacute bronchiolitis (see also IVc, IVi) XV.y XV - Pathology
XV.y - Path: Respiratory bronchiolitis (w/wo the RB-ILD-pattern) XV.ab XV - Pathology
XV.ab - Path: Pulmonary capillaritis XV.ba XV - Pathology
XV.ba - Path: Granulomatous lymphadenopathy XV.bi XV - Pathology
XV.bi - Path: Giant-cell interstitial pneumonia (GIP)-pattern XVI.a XVI - Imaging
XVI.a - Imaging: Diffuse haze XVI.b XVI - Imaging
XVI.b - Imaging: Ground-glass opacities (GGO) / shadowing XVI.d XVI - Imaging
XVI.d - Imaging: Alveolar opacities or haze with a batwing or butterfly distribution XVI.g XVI - Imaging
XVI.g - Imaging: Diffuse whiteout/alveolar shadowing (see also under IIb-ARDS) XVI.k XVI - Imaging
XVI.k - Imaging: An area or areas of consolidation XVI.v XVI - Imaging
XVI.v - Imaging: Centrilobular micronodules (can be diffuse) XVI.af XVI - Imaging
XVI.af - Imaging: Lung cysts or bullae (see also XVI ah/bf) XVI.ai XVI - Imaging
XVI.ai - Imaging: A 'tree-in-bud' pattern XVI.bl XVI - Imaging
XVI.bl - Imaging: An area or areas of avid tracer uptake in the lung/chest on 18F-PET scan XVII.a XVII - Infections & related conditions
XVII.a - Respiratory tract infection incl. pneumonia XVII.c XVII - Infections & related conditions
XVII.c - Aspergillosis, pulmonary (invasive, allergic [ABPA], or mycetoma) XVII.h XVII - Infections & related conditions
XVII.h - Nontuberculous pulmonary mycobacterial infection/superinfection XVIII.x XVIII - Distinctive patterns - 'Eye-catchers'
XVIII.x - Eye catcher: A batwing pattern on imaging XIX.a XIX - Cytological, biochemical features of/in BAL, pleural fluid or FNA
XIX.a - BAL: An excess proportion of lymphocytes XIX.b XIX - Cytological, biochemical features of/in BAL, pleural fluid or FNA
XIX.b - BAL: An excess proportion of neutrophils XIX.c XIX - Cytological, biochemical features of/in BAL, pleural fluid or FNA
XIX.c - BAL: An excess proportion of eosinophils XIX.d XIX - Cytological, biochemical features of/in BAL, pleural fluid or FNA
XIX.d - BAL: Gross or microscopic bleeding/hemorrhage XIX.f XIX - Cytological, biochemical features of/in BAL, pleural fluid or FNA
XIX.f - BAL: Foamy macrophages XIX.i XIX - Cytological, biochemical features of/in BAL, pleural fluid or FNA
XIX.i - BAL: Oil red O-stainable material in BAL macrophages othen than exogenous lipids XIX.n XIX - Cytological, biochemical features of/in BAL, pleural fluid or FNA
XIX.n - BAL: Brown-pigmented macrophages
1

Everolimus

I.a I - Interstitial/parenchymal lung disease
I.a - Pneumonitis (ILD), acute and/or severe (may cause ARDS) I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD) I.d I - Interstitial/parenchymal lung disease
I.d - Organizing pneumonia pattern (an area or areas of consolidation on imaging) I.f I - Interstitial/parenchymal lung disease
I.f - Acute fibrinous organizing pneumonia (AFOP) I.h I - Interstitial/parenchymal lung disease
I.h - Subclinical pulmonary infiltrates/ILD I.l I - Interstitial/parenchymal lung disease
I.l - Diffuse alveolar damage (DAD) (see alsoo under IIb and XVf) I.m I - Interstitial/parenchymal lung disease
I.m - ILD with a granulomatous component I.p I - Interstitial/parenchymal lung disease
I.p - Fatal pneumonitis (ILD) I.v I - Interstitial/parenchymal lung disease
I.v - Abnormal lung function/pulmonary physiology (PFTs) without necessarily imaging or clinical evidence I.y I - Interstitial/parenchymal lung disease
I.y - Progression, acceleration or exacerbation of preexisting ILD/fibrosis I.ad I - Interstitial/parenchymal lung disease
I.ad - Radiation recall pneumonitis II.b II - Pulmonary edema - Acute lung injury - ARDS
II.b - ARDS - Acute lung injury III.a III - Pulmonary/alveolar./airway hemorrhage/bleeding
III.a - Alveolar hemorrhage (AH), diffuse AH (DAH) III.h III - Pulmonary/alveolar./airway hemorrhage/bleeding
III.h - Major/massive hemoptysis IV.d IV - Airway involvement
IV.d - Cough (lone) V.h V - Pleural and/or pericardial involvement
V.h - Chylothorax V.i V - Pleural and/or pericardial involvement
V.i - Pleuritis (can cause chest pain) VI.a VI - Pulmonary vasculopathies
VI.a - Pulmonary embolism - Venous thrombosis/thromboembolism VIII.a VIII - Central-large-upper airway (incl. pharyngeal-nasal) involvement
VIII.a - Angioedema (may cause UAO, asphyxia and death) XV.a XV - Pathology
XV.a - Path: NSIP-cellular pattern (see also Ia, Ib) XV.c XV - Pathology
XV.c - Path: Organizing pneumonia (OP/BOOP) pattern (see also Id) XV.d XV - Pathology
XV.d - Path: Acute fibrinous organizing pneumonia (AFOP-pattern) (see also If) XV.e XV - Pathology
XV.e - Path: ILD with a granulomatous component (see also Im) XV.g XV - Pathology
XV.g - Path: Alveolar hemorrhage (see also IIIa) XVI.b XVI - Imaging
XVI.b - Imaging: Ground-glass opacities (GGO) / shadowing XVI.bl XVI - Imaging
XVI.bl - Imaging: An area or areas of avid tracer uptake in the lung/chest on 18F-PET scan XVII.e XVII - Infections & related conditions
XVII.e - Pneumocystis jiroveci pneumonia
2

FOLFOX chemotherapy regimen

1

Gases

4

Immune checkpoint inhibitors (ICI) - ICI combinatorial Rx

I.a I - Interstitial/parenchymal lung disease
I.a - Pneumonitis (ILD), acute and/or severe (may cause ARDS) I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD) I.c I - Interstitial/parenchymal lung disease
I.c - Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia) I.d I - Interstitial/parenchymal lung disease
I.d - Organizing pneumonia pattern (an area or areas of consolidation on imaging) I.e I - Interstitial/parenchymal lung disease
I.e - Acute eosinophilic pneumonia (AEP) I.f I - Interstitial/parenchymal lung disease
I.f - Acute fibrinous organizing pneumonia (AFOP) I.g I - Interstitial/parenchymal lung disease
I.g - Pulmonary fibrosis I.u I - Interstitial/parenchymal lung disease
I.u - Relapsing or migrating pneumonitis/pneumonia (see also Id) I.v I - Interstitial/parenchymal lung disease
I.v - Abnormal lung function/pulmonary physiology (PFTs) without necessarily imaging or clinical evidence I.w I - Interstitial/parenchymal lung disease
I.w - Rapidly progressive ILD/pulmonary fibrosis (Hamman-Rich syndrome) I.y I - Interstitial/parenchymal lung disease
I.y - Progression, acceleration or exacerbation of preexisting ILD/fibrosis I.aa I - Interstitial/parenchymal lung disease
I.aa - Delayed ILD, -pneumonitis, -fibrosis I.ad I - Interstitial/parenchymal lung disease
I.ad - Radiation recall pneumonitis I.aj I - Interstitial/parenchymal lung disease
I.aj - Shrinking lung syndrome I.ax I - Interstitial/parenchymal lung disease
I.ax - Chronic pneumonitis II.b II - Pulmonary edema - Acute lung injury - ARDS
II.b - ARDS - Acute lung injury II.d II - Pulmonary edema - Acute lung injury - ARDS
II.d - Pulmonary edema, cardiogenic III.m III - Pulmonary/alveolar./airway hemorrhage/bleeding
III.m - Coagulopathy IV.a IV - Airway involvement
IV.a - Bronchospasm - Wheezing - Asthma IV.c IV - Airway involvement
IV.c - Obliterative bronchiolitis (a pattern consistent with) (see also IVn, XVx) IV.n IV - Airway involvement
IV.n - Obstructive airway dysfunction (see also IVc, XVx) IV.y IV - Airway involvement
IV.y - Eosinophilic airway disease (asthma, bronchitis, bronchiolitis) V.a V - Pleural and/or pericardial involvement
V.a - Pleural effusion (uni- or bilateral) (can accompany DI-LDs) V.s V - Pleural and/or pericardial involvement
V.s - Serositis - Polyserositis VI.b VI - Pulmonary vasculopathies
VI.b - Pulmonary arterial hypertension VII.a VII - Mediastinal involvement
VII.a - Lymphadenopathy (intrathoracic) VIII.t VIII - Central-large-upper airway (incl. pharyngeal-nasal) involvement
VIII.t - Vocal cord paresis/paralysis IX.a IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.a - Diaphragm/inspiratory muscle weakness/paralysis (w/wo ARF) IX.d IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.d - Respiratory failure from ventilatory depression (due to neuromuscular blockade/paralysis) IX.r IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.r - Myasthenia gravis - Myasthenic-like syndrome IX.ab IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.ab - Guillain-Barré (or GB-like) syndrome (w/wo ARF) IX.ac IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.ac - Myositis of the respiratory muscles (May lead to respiratory muscle paralysis) X.a X - Systemic/Distant conditions, syndromes and reactions
X.a - DRES syndrome - DRESS-like reaction X.c X - Systemic/Distant conditions, syndromes and reactions
X.c - Capillary leak syndrome (CLS) X.d X - Systemic/Distant conditions, syndromes and reactions
X.d - Lupus - Lupus syndrome (see also Vd) X.e X - Systemic/Distant conditions, syndromes and reactions
X.e - Autoimmunity-Autoimmune conditions (+ANA, +anti-ds-DNA, +ANCAs, other auto-Abs) X.f X - Systemic/Distant conditions, syndromes and reactions
X.f - Anaphylaxis-Anaphylactoid reaction (can be fatal) X.g X - Systemic/Distant conditions, syndromes and reactions
X.g - Hypersensitivity reaction (may manifest with fever and/or skin, throat or airway involvement) X.h X - Systemic/Distant conditions, syndromes and reactions
X.h - Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) X.j X - Systemic/Distant conditions, syndromes and reactions
X.j - Myopathy-Myositis-Polymyositis (see also under Xba) X.k X - Systemic/Distant conditions, syndromes and reactions
X.k - Sarcoid-like granulomatosis (endo-/extrathoracic) X.m X - Systemic/Distant conditions, syndromes and reactions
X.m - Vascultis (pulmonary, extrathoracic or systemic)-ANCA status unknown or negative) X.s X - Systemic/Distant conditions, syndromes and reactions
X.s - Vasculitis, pulmonary (w/wo AH), extrapulmonary, systemic: ANCA-positive X.u X - Systemic/Distant conditions, syndromes and reactions
X.u - Multiple organ dysfunction/failure (MODS/MOF) X.am X - Systemic/Distant conditions, syndromes and reactions
X.am - Immune-related adverse effect/toxicity X.an X - Systemic/Distant conditions, syndromes and reactions
X.an - Cytokine release syndrome - Cytokine storm X.aw X - Systemic/Distant conditions, syndromes and reactions
X.aw - Connective tissue disease X.ay X - Systemic/Distant conditions, syndromes and reactions
X.ay - Polymyalgia rheumatica XI.n XI - Miscellaneous
XI.n - Neutropenia, agranulocytosis (w/wo infection/sepsis) XI.y XI - Miscellaneous
XI.y - Adrenal suppression XI.ag XI - Miscellaneous
XI.ag - Vertebral compression fracture XI.au XI - Miscellaneous
XI.au - Graft vs. host disease in transplant recipients XI.av XI - Miscellaneous
XI.av - Deterioration of graft function in SOT recipients XI.ba XI - Miscellaneous
XI.ba - Nonrespiratory AE of interest XII.a XII - Cardiovascular involvement / toxicity
XII.a - Left or biventricular dysfunction/failure XII.c XII - Cardiovascular involvement / toxicity
XII.c - Pericardial effusion (w/wo tamponade) XII.d XII - Cardiovascular involvement / toxicity
XII.d - Myocarditis (can be fulminant) XII.e XII - Cardiovascular involvement / toxicity
XII.e - Takotsubo (stress) cardiomyopathy XII.g XII - Cardiovascular involvement / toxicity
XII.g - Coronary artery disease (acute) - Myocardial ischemia/infarction XII.l XII - Cardiovascular involvement / toxicity
XII.l - Cardiac arrhythmias or dysrhythmias (AF, VT, VF, TdP) XII.n XII - Cardiovascular involvement / toxicity
XII.n - Cardiovascular collapse - Cardiogenic shock - Hypotension XII.s XII - Cardiovascular involvement / toxicity
XII.s - Heart block (bundle branch- or AV-) XII.ai XII - Cardiovascular involvement / toxicity
XII.ai - Cardiotoxicity XII.ax XII - Cardiovascular involvement / toxicity
XII.ax - Necrotizing myocarditis (w/o evidence for CAD) XII.ba XII - Cardiovascular involvement / toxicity
XII.ba - Sudden cardiac death XV.a XV - Pathology
XV.a - Path: NSIP-cellular pattern (see also Ia, Ib) XV.b XV - Pathology
XV.b - Path: Eosinophilic pneumonia (subacute or acute) (see also Ic) XV.c XV - Pathology
XV.c - Path: Organizing pneumonia (OP/BOOP) pattern (see also Id) XV.d XV - Pathology
XV.d - Path: Acute fibrinous organizing pneumonia (AFOP-pattern) (see also If) XV.e XV - Pathology
XV.e - Path: ILD with a granulomatous component (see also Im) XV.f XV - Pathology
XV.f - Path: Diffuse alveolar damage (DAD-pattern) (see also IL) XV.l XV - Pathology
XV.l - Path: Pulmonary fibrosis (not otherwise specified or unclassifiable) XV.v XV - Pathology
XV.v - Path: Micronodular organizing pneumonia/BOOP XV.x XV - Pathology
XV.x - Path: Acute/subacute bronchiolitis (see also IVc, IVi) XV.ba XV - Pathology
XV.ba - Path: Granulomatous lymphadenopathy XV.co XV - Pathology
XV.co - Path: Foamy inclusions in alveolar macrophages and/or in other lung cells XV.cp XV - Pathology
XV.cp - Path: Pneumocyte vacuolization XVI.k XVI - Imaging
XVI.k - Imaging: An area or areas of consolidation XVI.v XVI - Imaging
XVI.v - Imaging: Centrilobular micronodules (can be diffuse) XVI.bh XVI - Imaging
XVI.bh - Imaging: F18-PET scan positive lympadenopathy XVI.bt XVI - Imaging
XVI.bt - Imaging: A subsolid lung nodule or nodules XVII.b XVII - Infections & related conditions
XVII.b - Opportunistic pulmonary/systemic infections XVII.c XVII - Infections & related conditions
XVII.c - Aspergillosis, pulmonary (invasive, allergic [ABPA], or mycetoma) XVII.e XVII - Infections & related conditions
XVII.e - Pneumocystis jiroveci pneumonia XVII.g XVII - Infections & related conditions
XVII.g - Tuberculosis (pulmonary, pulmonary, extrapulmonary or disseminated). Reactivation or de novo XVII.q XVII - Infections & related conditions
XVII.q - Viral pneumonia XVII.r XVII - Infections & related conditions
XVII.r - Fungal infection (pulmonary/extrapulmonary) XIX.a XIX - Cytological, biochemical features of/in BAL, pleural fluid or FNA
XIX.a - BAL: An excess proportion of lymphocytes XIX.b XIX - Cytological, biochemical features of/in BAL, pleural fluid or FNA
XIX.b - BAL: An excess proportion of neutrophils XIX.c XIX - Cytological, biochemical features of/in BAL, pleural fluid or FNA
XIX.c - BAL: An excess proportion of eosinophils
1

Interferon alpha/beta

I.a I - Interstitial/parenchymal lung disease
I.a - Pneumonitis (ILD), acute and/or severe (may cause ARDS) I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD) I.d I - Interstitial/parenchymal lung disease
I.d - Organizing pneumonia pattern (an area or areas of consolidation on imaging) I.g I - Interstitial/parenchymal lung disease
I.g - Pulmonary fibrosis I.m I - Interstitial/parenchymal lung disease
I.m - ILD with a granulomatous component I.v I - Interstitial/parenchymal lung disease
I.v - Abnormal lung function/pulmonary physiology (PFTs) without necessarily imaging or clinical evidence I.y I - Interstitial/parenchymal lung disease
I.y - Progression, acceleration or exacerbation of preexisting ILD/fibrosis II.a II - Pulmonary edema - Acute lung injury - ARDS
II.a - Pulmonary edema, noncardiogenic (NCPE) II.b II - Pulmonary edema - Acute lung injury - ARDS
II.b - ARDS - Acute lung injury IV.a IV - Airway involvement
IV.a - Bronchospasm - Wheezing - Asthma IV.d IV - Airway involvement
IV.d - Cough (lone) IV.w IV - Airway involvement
IV.w - Plugs/casts in the airways V.a V - Pleural and/or pericardial involvement
V.a - Pleural effusion (uni- or bilateral) (can accompany DI-LDs) VI.b VI - Pulmonary vasculopathies
VI.b - Pulmonary arterial hypertension VI.d VI - Pulmonary vasculopathies
VI.d - Pulmonary vasculitis or capillaritis VI.f VI - Pulmonary vasculopathies
VI.f - Hemolytic and uremic syndrome (HUS). See also under Xaf VII.a VII - Mediastinal involvement
VII.a - Lymphadenopathy (intrathoracic) VII.e VII - Mediastinal involvement
VII.e - Granulomatous mediastinal lymphadenopathy VIII.a VIII - Central-large-upper airway (incl. pharyngeal-nasal) involvement
VIII.a - Angioedema (may cause UAO, asphyxia and death) X.b X - Systemic/Distant conditions, syndromes and reactions
X.b - Antiphospholipid antibodies w/wo the APL syndrome X.c X - Systemic/Distant conditions, syndromes and reactions
X.c - Capillary leak syndrome (CLS) X.d X - Systemic/Distant conditions, syndromes and reactions
X.d - Lupus - Lupus syndrome (see also Vd) X.f X - Systemic/Distant conditions, syndromes and reactions
X.f - Anaphylaxis-Anaphylactoid reaction (can be fatal) X.j X - Systemic/Distant conditions, syndromes and reactions
X.j - Myopathy-Myositis-Polymyositis (see also under Xba) X.k X - Systemic/Distant conditions, syndromes and reactions
X.k - Sarcoid-like granulomatosis (endo-/extrathoracic) X.u X - Systemic/Distant conditions, syndromes and reactions
X.u - Multiple organ dysfunction/failure (MODS/MOF) XI.n XI - Miscellaneous
XI.n - Neutropenia, agranulocytosis (w/wo infection/sepsis) XV.a XV - Pathology
XV.a - Path: NSIP-cellular pattern (see also Ia, Ib) XV.c XV - Pathology
XV.c - Path: Organizing pneumonia (OP/BOOP) pattern (see also Id) XV.e XV - Pathology
XV.e - Path: ILD with a granulomatous component (see also Im) XV.f XV - Pathology
XV.f - Path: Diffuse alveolar damage (DAD-pattern) (see also IL) XV.k XV - Pathology
XV.k - Path: Desquamative interstitial pneumonia (DIP-pattern) XVII.g XVII - Infections & related conditions
XVII.g - Tuberculosis (pulmonary, pulmonary, extrapulmonary or disseminated). Reactivation or de novo
2

Interferon beta1a (inhaled)

1

Iodine, radioactive (131I)

1

Iodixanol

1

Ipilimumab

I.a I - Interstitial/parenchymal lung disease
I.a - Pneumonitis (ILD), acute and/or severe (may cause ARDS) I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD) I.d I - Interstitial/parenchymal lung disease
I.d - Organizing pneumonia pattern (an area or areas of consolidation on imaging) I.m I - Interstitial/parenchymal lung disease
I.m - ILD with a granulomatous component I.v I - Interstitial/parenchymal lung disease
I.v - Abnormal lung function/pulmonary physiology (PFTs) without necessarily imaging or clinical evidence II.b II - Pulmonary edema - Acute lung injury - ARDS
II.b - ARDS - Acute lung injury V.a V - Pleural and/or pericardial involvement
V.a - Pleural effusion (uni- or bilateral) (can accompany DI-LDs) V.m V - Pleural and/or pericardial involvement
V.m - Pleuropericarditis - Pleuropericardial effusion (ANA unknown or negative) VII.e VII - Mediastinal involvement
VII.e - Granulomatous mediastinal lymphadenopathy IX.j IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.j - Phrenic nerve injury - Hemi- or bilateral diaphragmatic paralysis IX.r IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.r - Myasthenia gravis - Myasthenic-like syndrome IX.ab IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.ab - Guillain-Barré (or GB-like) syndrome (w/wo ARF) X.a X - Systemic/Distant conditions, syndromes and reactions
X.a - DRES syndrome - DRESS-like reaction X.e X - Systemic/Distant conditions, syndromes and reactions
X.e - Autoimmunity-Autoimmune conditions (+ANA, +anti-ds-DNA, +ANCAs, other auto-Abs) X.g X - Systemic/Distant conditions, syndromes and reactions
X.g - Hypersensitivity reaction (may manifest with fever and/or skin, throat or airway involvement) X.j X - Systemic/Distant conditions, syndromes and reactions
X.j - Myopathy-Myositis-Polymyositis (see also under Xba) X.k X - Systemic/Distant conditions, syndromes and reactions
X.k - Sarcoid-like granulomatosis (endo-/extrathoracic) X.l X - Systemic/Distant conditions, syndromes and reactions
X.l - Systemic granulomatosis other than Xk X.o X - Systemic/Distant conditions, syndromes and reactions
X.o - Neutrophilic dermatosis (Pyoderma, Sweet syndrome) X.am X - Systemic/Distant conditions, syndromes and reactions
X.am - Immune-related adverse effect/toxicity XII.c XII - Cardiovascular involvement / toxicity
XII.c - Pericardial effusion (w/wo tamponade) XII.d XII - Cardiovascular involvement / toxicity
XII.d - Myocarditis (can be fulminant) XII.az XII - Cardiovascular involvement / toxicity
XII.az - Fulminant myocarditis (See also under XIId) XV.c XV - Pathology
XV.c - Path: Organizing pneumonia (OP/BOOP) pattern (see also Id) XV.ci XV - Pathology
XV.ci - Path: Fibrinous pericarditis XVI.bh XVI - Imaging
XVI.bh - Imaging: F18-PET scan positive lympadenopathy XVII.b XVII - Infections & related conditions
XVII.b - Opportunistic pulmonary/systemic infections XVII.c XVII - Infections & related conditions
XVII.c - Aspergillosis, pulmonary (invasive, allergic [ABPA], or mycetoma) XIX.a XIX - Cytological, biochemical features of/in BAL, pleural fluid or FNA
XIX.a - BAL: An excess proportion of lymphocytes
1

Lomustine (CCNU)

2

Melphalan

2

Methotrexate

I.a I - Interstitial/parenchymal lung disease
I.a - Pneumonitis (ILD), acute and/or severe (may cause ARDS) I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD) I.d I - Interstitial/parenchymal lung disease
I.d - Organizing pneumonia pattern (an area or areas of consolidation on imaging) I.g I - Interstitial/parenchymal lung disease
I.g - Pulmonary fibrosis I.h I - Interstitial/parenchymal lung disease
I.h - Subclinical pulmonary infiltrates/ILD I.k I - Interstitial/parenchymal lung disease
I.k - Lung nodule or nodules I.l I - Interstitial/parenchymal lung disease
I.l - Diffuse alveolar damage (DAD) (see alsoo under IIb and XVf) I.m I - Interstitial/parenchymal lung disease
I.m - ILD with a granulomatous component I.q I - Interstitial/parenchymal lung disease
I.q - Pulmonary nodulosis I.v I - Interstitial/parenchymal lung disease
I.v - Abnormal lung function/pulmonary physiology (PFTs) without necessarily imaging or clinical evidence I.w I - Interstitial/parenchymal lung disease
I.w - Rapidly progressive ILD/pulmonary fibrosis (Hamman-Rich syndrome) I.aa I - Interstitial/parenchymal lung disease
I.aa - Delayed ILD, -pneumonitis, -fibrosis II.a II - Pulmonary edema - Acute lung injury - ARDS
II.a - Pulmonary edema, noncardiogenic (NCPE) II.b II - Pulmonary edema - Acute lung injury - ARDS
II.b - ARDS - Acute lung injury III.a III - Pulmonary/alveolar./airway hemorrhage/bleeding
III.a - Alveolar hemorrhage (AH), diffuse AH (DAH) IV.a IV - Airway involvement
IV.a - Bronchospasm - Wheezing - Asthma IV.d IV - Airway involvement
IV.d - Cough (lone) V.a V - Pleural and/or pericardial involvement
V.a - Pleural effusion (uni- or bilateral) (can accompany DI-LDs) V.b V - Pleural and/or pericardial involvement
V.b - Eosinophilic pleural effusion V.e V - Pleural and/or pericardial involvement
V.e - Hemothorax - Serosanguineous pleural effusion V.i V - Pleural and/or pericardial involvement
V.i - Pleuritis (can cause chest pain) V.n V - Pleural and/or pericardial involvement
V.n - Hemopericardium - Bloody pericardial effusion V.s V - Pleural and/or pericardial involvement
V.s - Serositis - Polyserositis VI.a VI - Pulmonary vasculopathies
VI.a - Pulmonary embolism - Venous thrombosis/thromboembolism VII.a VII - Mediastinal involvement
VII.a - Lymphadenopathy (intrathoracic) VIII.a VIII - Central-large-upper airway (incl. pharyngeal-nasal) involvement
VIII.a - Angioedema (may cause UAO, asphyxia and death) VIII.aj VIII - Central-large-upper airway (incl. pharyngeal-nasal) involvement
VIII.aj - Endobronchial lymphoproliferative disorder X.f X - Systemic/Distant conditions, syndromes and reactions
X.f - Anaphylaxis-Anaphylactoid reaction (can be fatal) X.k X - Systemic/Distant conditions, syndromes and reactions
X.k - Sarcoid-like granulomatosis (endo-/extrathoracic) X.u X - Systemic/Distant conditions, syndromes and reactions
X.u - Multiple organ dysfunction/failure (MODS/MOF) XI.b XI - Miscellaneous
XI.b - Chest pain (acute or subacute), lone or prominent XI.c XI - Miscellaneous
XI.c - Pleuritic chest pain XII.c XII - Cardiovascular involvement / toxicity
XII.c - Pericardial effusion (w/wo tamponade) XIII.b XIII - Neoplastic conditions
XIII.b - Lymphoproliferative disease (pulmonary, endobronchial, endothoracic) XIII.g XIII - Neoplastic conditions
XIII.g - Lymphomatoid granulomatosis (pulmonary, endothoracic) XIII.k XIII - Neoplastic conditions
XIII.k - Lymphoproliferative disease (extrathoracic) XV.a XV - Pathology
XV.a - Path: NSIP-cellular pattern (see also Ia, Ib) XV.c XV - Pathology
XV.c - Path: Organizing pneumonia (OP/BOOP) pattern (see also Id) XV.e XV - Pathology
XV.e - Path: ILD with a granulomatous component (see also Im) XV.f XV - Pathology
XV.f - Path: Diffuse alveolar damage (DAD-pattern) (see also IL) XV.h XV - Pathology
XV.h - Path: NSIP-fibrotic pattern XV.i XV - Pathology
XV.i - Path: Pneumocyte atypia (reactive epithelial cells) (a.k.a. the "Napoleon Hat" sign) XV.w XV - Pathology
XV.w - Path: Pulmonary edema (see also II/IIa) XV.bq XV - Pathology
XV.bq - Path: Lymphoproliferative disease, endothoracic XVI.b XVI - Imaging
XVI.b - Imaging: Ground-glass opacities (GGO) / shadowing XVI.k XVI - Imaging
XVI.k - Imaging: An area or areas of consolidation XVI.w XVI - Imaging
XVI.w - Imaging: Lung nodule or nodules XVI.bc XVI - Imaging
XVI.bc - Imaging: Intrathoracic lymph node enlargement XVII.b XVII - Infections & related conditions
XVII.b - Opportunistic pulmonary/systemic infections XVII.d XVII - Infections & related conditions
XVII.d - Pneumocystis jiroveci pulmonary colonization XVII.e XVII - Infections & related conditions
XVII.e - Pneumocystis jiroveci pneumonia XVII.h XVII - Infections & related conditions
XVII.h - Nontuberculous pulmonary mycobacterial infection/superinfection XVII.q XVII - Infections & related conditions
XVII.q - Viral pneumonia XIX.a XIX - Cytological, biochemical features of/in BAL, pleural fluid or FNA
XIX.a - BAL: An excess proportion of lymphocytes XIX.b XIX - Cytological, biochemical features of/in BAL, pleural fluid or FNA
XIX.b - BAL: An excess proportion of neutrophils XIX.c XIX - Cytological, biochemical features of/in BAL, pleural fluid or FNA
XIX.c - BAL: An excess proportion of eosinophils
5

Mitomycin C

I.a I - Interstitial/parenchymal lung disease
I.a - Pneumonitis (ILD), acute and/or severe (may cause ARDS) I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD) I.g I - Interstitial/parenchymal lung disease
I.g - Pulmonary fibrosis I.h I - Interstitial/parenchymal lung disease
I.h - Subclinical pulmonary infiltrates/ILD I.l I - Interstitial/parenchymal lung disease
I.l - Diffuse alveolar damage (DAD) (see alsoo under IIb and XVf) I.v I - Interstitial/parenchymal lung disease
I.v - Abnormal lung function/pulmonary physiology (PFTs) without necessarily imaging or clinical evidence I.w I - Interstitial/parenchymal lung disease
I.w - Rapidly progressive ILD/pulmonary fibrosis (Hamman-Rich syndrome) II.a II - Pulmonary edema - Acute lung injury - ARDS
II.a - Pulmonary edema, noncardiogenic (NCPE) II.b II - Pulmonary edema - Acute lung injury - ARDS
II.b - ARDS - Acute lung injury II.c II - Pulmonary edema - Acute lung injury - ARDS
II.c - ARDS and the hemolytic-uremic syndrome (HUS) III.a III - Pulmonary/alveolar./airway hemorrhage/bleeding
III.a - Alveolar hemorrhage (AH), diffuse AH (DAH) VI.b VI - Pulmonary vasculopathies
VI.b - Pulmonary arterial hypertension VI.c VI - Pulmonary vasculopathies
VI.c - Pulmonary veno-occlusive disease VI.f VI - Pulmonary vasculopathies
VI.f - Hemolytic and uremic syndrome (HUS). See also under Xaf VI.p VI - Pulmonary vasculopathies
VI.p - Angiomatoid pulmonary vasculopathy VIII.c VIII - Central-large-upper airway (incl. pharyngeal-nasal) involvement
VIII.c - Upper airway obstruction other than angioedema or hematoma X.k X - Systemic/Distant conditions, syndromes and reactions
X.k - Sarcoid-like granulomatosis (endo-/extrathoracic) XV.a XV - Pathology
XV.a - Path: NSIP-cellular pattern (see also Ia, Ib) XV.i XV - Pathology
XV.i - Path: Pneumocyte atypia (reactive epithelial cells) (a.k.a. the "Napoleon Hat" sign) XV.ak XV - Pathology
XV.ak - Path: Pulmonary veno-occlusive disease (PVOD)
2

Nitrofurantoin

I.a I - Interstitial/parenchymal lung disease
I.a - Pneumonitis (ILD), acute and/or severe (may cause ARDS) I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD) I.c I - Interstitial/parenchymal lung disease
I.c - Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia) I.d I - Interstitial/parenchymal lung disease
I.d - Organizing pneumonia pattern (an area or areas of consolidation on imaging) I.e I - Interstitial/parenchymal lung disease
I.e - Acute eosinophilic pneumonia (AEP) I.g I - Interstitial/parenchymal lung disease
I.g - Pulmonary fibrosis I.l I - Interstitial/parenchymal lung disease
I.l - Diffuse alveolar damage (DAD) (see alsoo under IIb and XVf) I.r I - Interstitial/parenchymal lung disease
I.r - An imaging pattern consistent with DIP I.v I - Interstitial/parenchymal lung disease
I.v - Abnormal lung function/pulmonary physiology (PFTs) without necessarily imaging or clinical evidence I.ax I - Interstitial/parenchymal lung disease
I.ax - Chronic pneumonitis II.a II - Pulmonary edema - Acute lung injury - ARDS
II.a - Pulmonary edema, noncardiogenic (NCPE) II.b II - Pulmonary edema - Acute lung injury - ARDS
II.b - ARDS - Acute lung injury II.j II - Pulmonary edema - Acute lung injury - ARDS
II.j - Transient pulmonary opacities/infiltrates (see also under Iav) III.a III - Pulmonary/alveolar./airway hemorrhage/bleeding
III.a - Alveolar hemorrhage (AH), diffuse AH (DAH) IV.a IV - Airway involvement
IV.a - Bronchospasm - Wheezing - Asthma IV.ae IV - Airway involvement
IV.ae - Tracheobronchitis-like clinical pattern V.a V - Pleural and/or pericardial involvement
V.a - Pleural effusion (uni- or bilateral) (can accompany DI-LDs) V.b V - Pleural and/or pericardial involvement
V.b - Eosinophilic pleural effusion V.d V - Pleural and/or pericardial involvement
V.d - Pleural/pericardial effusion, ANA positive (DI lupus) V.i V - Pleural and/or pericardial involvement
V.i - Pleuritis (can cause chest pain) VI.d VI - Pulmonary vasculopathies
VI.d - Pulmonary vasculitis or capillaritis VII.a VII - Mediastinal involvement
VII.a - Lymphadenopathy (intrathoracic) VIII.b VIII - Central-large-upper airway (incl. pharyngeal-nasal) involvement
VIII.b - Hematoma of/around central airway wall potentially causing UAO IX.i IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.i - Respiratory arrest - Apnea X.a X - Systemic/Distant conditions, syndromes and reactions
X.a - DRES syndrome - DRESS-like reaction X.d X - Systemic/Distant conditions, syndromes and reactions
X.d - Lupus - Lupus syndrome (see also Vd) X.e X - Systemic/Distant conditions, syndromes and reactions
X.e - Autoimmunity-Autoimmune conditions (+ANA, +anti-ds-DNA, +ANCAs, other auto-Abs) X.f X - Systemic/Distant conditions, syndromes and reactions
X.f - Anaphylaxis-Anaphylactoid reaction (can be fatal) X.s X - Systemic/Distant conditions, syndromes and reactions
X.s - Vasculitis, pulmonary (w/wo AH), extrapulmonary, systemic: ANCA-positive XI.b XI - Miscellaneous
XI.b - Chest pain (acute or subacute), lone or prominent XI.c XI - Miscellaneous
XI.c - Pleuritic chest pain XV.a XV - Pathology
XV.a - Path: NSIP-cellular pattern (see also Ia, Ib) XV.b XV - Pathology
XV.b - Path: Eosinophilic pneumonia (subacute or acute) (see also Ic) XV.c XV - Pathology
XV.c - Path: Organizing pneumonia (OP/BOOP) pattern (see also Id) XV.e XV - Pathology
XV.e - Path: ILD with a granulomatous component (see also Im) XV.f XV - Pathology
XV.f - Path: Diffuse alveolar damage (DAD-pattern) (see also IL) XV.h XV - Pathology
XV.h - Path: NSIP-fibrotic pattern XV.j XV - Pathology
XV.j - Path: Pulmonary fibrosis (UIP-pattern) XV.k XV - Pathology
XV.k - Path: Desquamative interstitial pneumonia (DIP-pattern) XV.x XV - Pathology
XV.x - Path: Acute/subacute bronchiolitis (see also IVc, IVi) XV.ac XV - Pathology
XV.ac - Path: Pulmonary vasculitis other than capillaritis XV.af XV - Pathology
XV.af - Path: Granulomatous pulmonary vasculitis XV.bi XV - Pathology
XV.bi - Path: Giant-cell interstitial pneumonia (GIP)-pattern XV.bl XV - Pathology
XV.bl - Path: Resolving alveolar damage XVI.b XVI - Imaging
XVI.b - Imaging: Ground-glass opacities (GGO) / shadowing XVI.f XVI - Imaging
XVI.f - Imaging: Bibasilar opacities/shadowing XVI.l XVI - Imaging
XVI.l - Imaging: Peribronchovascular areas of consolidation XVI.bc XVI - Imaging
XVI.bc - Imaging: Intrathoracic lymph node enlargement XVI.bp XVI - Imaging
XVI.bp - Imaging: Reverse ventilation-perfusion mismatch
1

Oxygen (dioxygen, O2)

2

Radiation therapy (early effects)

I.a I - Interstitial/parenchymal lung disease
I.a - Pneumonitis (ILD), acute and/or severe (may cause ARDS) I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD) I.c I - Interstitial/parenchymal lung disease
I.c - Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia) I.d I - Interstitial/parenchymal lung disease
I.d - Organizing pneumonia pattern (an area or areas of consolidation on imaging) I.v I - Interstitial/parenchymal lung disease
I.v - Abnormal lung function/pulmonary physiology (PFTs) without necessarily imaging or clinical evidence I.y I - Interstitial/parenchymal lung disease
I.y - Progression, acceleration or exacerbation of preexisting ILD/fibrosis I.ab I - Interstitial/parenchymal lung disease
I.ab - Radiation-induced lung injury (RILI) I.ac I - Interstitial/parenchymal lung disease
I.ac - Acute radiation pneumonitis II.b II - Pulmonary edema - Acute lung injury - ARDS
II.b - ARDS - Acute lung injury V.a V - Pleural and/or pericardial involvement
V.a - Pleural effusion (uni- or bilateral) (can accompany DI-LDs) V.h V - Pleural and/or pericardial involvement
V.h - Chylothorax VIII.c VIII - Central-large-upper airway (incl. pharyngeal-nasal) involvement
VIII.c - Upper airway obstruction other than angioedema or hematoma IX.h IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.h - Dyspnea, unexplained otherwise XII.k XII - Cardiovascular involvement / toxicity
XII.k - Constrictive pericarditis - Pericardial thickening XV.a XV - Pathology
XV.a - Path: NSIP-cellular pattern (see also Ia, Ib) XV.b XV - Pathology
XV.b - Path: Eosinophilic pneumonia (subacute or acute) (see also Ic) XV.c XV - Pathology
XV.c - Path: Organizing pneumonia (OP/BOOP) pattern (see also Id) XV.d XV - Pathology
XV.d - Path: Acute fibrinous organizing pneumonia (AFOP-pattern) (see also If) XV.f XV - Pathology
XV.f - Path: Diffuse alveolar damage (DAD-pattern) (see also IL) XV.h XV - Pathology
XV.h - Path: NSIP-fibrotic pattern XVI.bl XVI - Imaging
XVI.bl - Imaging: An area or areas of avid tracer uptake in the lung/chest on 18F-PET scan XIX.a XIX - Cytological, biochemical features of/in BAL, pleural fluid or FNA
XIX.a - BAL: An excess proportion of lymphocytes XIX.c XIX - Cytological, biochemical features of/in BAL, pleural fluid or FNA
XIX.c - BAL: An excess proportion of eosinophils
3

Radiation therapy (medium term & late effects)

I.c I - Interstitial/parenchymal lung disease
I.c - Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia) I.d I - Interstitial/parenchymal lung disease
I.d - Organizing pneumonia pattern (an area or areas of consolidation on imaging) I.g I - Interstitial/parenchymal lung disease
I.g - Pulmonary fibrosis I.h I - Interstitial/parenchymal lung disease
I.h - Subclinical pulmonary infiltrates/ILD I.o I - Interstitial/parenchymal lung disease
I.o - Focal/localized area of pneumonitis/fibrosis I.v I - Interstitial/parenchymal lung disease
I.v - Abnormal lung function/pulmonary physiology (PFTs) without necessarily imaging or clinical evidence I.x I - Interstitial/parenchymal lung disease
I.x - Pleuroparenchymal fibroelastosis (PPFE) II.b II - Pulmonary edema - Acute lung injury - ARDS
II.b - ARDS - Acute lung injury III.c III - Pulmonary/alveolar./airway hemorrhage/bleeding
III.c - Hemoptysis IV.h IV - Airway involvement
IV.h - Large airway necrosis IV.k IV - Airway involvement
IV.k - Bronchiectasis IV.m IV - Airway involvement
IV.m - Bronchial stenosis/stricture V.a V - Pleural and/or pericardial involvement
V.a - Pleural effusion (uni- or bilateral) (can accompany DI-LDs) V.b V - Pleural and/or pericardial involvement
V.b - Eosinophilic pleural effusion V.c V - Pleural and/or pericardial involvement
V.c - Pleural thickening V.f V - Pleural and/or pericardial involvement
V.f - Pneumothorax V.h V - Pleural and/or pericardial involvement
V.h - Chylothorax V.l V - Pleural and/or pericardial involvement
V.l - Malignant pleural mesothelioma V.m V - Pleural and/or pericardial involvement
V.m - Pleuropericarditis - Pleuropericardial effusion (ANA unknown or negative) V.t V - Pleural and/or pericardial involvement
V.t - The apical cap VI.c VI - Pulmonary vasculopathies
VI.c - Pulmonary veno-occlusive disease VI.t VI - Pulmonary vasculopathies
VI.t - Pulmonary artery aneurysm(s) VI.ab VI - Pulmonary vasculopathies
VI.ab - Pulmonary artery stenosis VII.d VII - Mediastinal involvement
VII.d - Fibrosing mediastinitis VII.i VII - Mediastinal involvement
VII.i - Mediastinitis VII.j VII - Mediastinal involvement
VII.j - Compression of mediastinal structures/organs VII.l VII - Mediastinal involvement
VII.l - Calcification of mediastinal lymph nodes VIII.c VIII - Central-large-upper airway (incl. pharyngeal-nasal) involvement
VIII.c - Upper airway obstruction other than angioedema or hematoma VIII.j VIII - Central-large-upper airway (incl. pharyngeal-nasal) involvement
VIII.j - Laryngeal disorder-Laryngeal nerve palsy (dysphonia, hoarseness) VIII.r VIII - Central-large-upper airway (incl. pharyngeal-nasal) involvement
VIII.r - Tracheal/large airway necrosis, chondronecrosis, perforation VIII.t VIII - Central-large-upper airway (incl. pharyngeal-nasal) involvement
VIII.t - Vocal cord paresis/paralysis VIII.ab VIII - Central-large-upper airway (incl. pharyngeal-nasal) involvement
VIII.ab - Airway (e.g. tracheoesophageal) fistula IX.a IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.a - Diaphragm/inspiratory muscle weakness/paralysis (w/wo ARF) IX.aj IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.aj - Paraspinal muscle myositis/myopathy/neuromyopathy +- the dropped head syndrome XI.g XI - Miscellaneous
XI.g - Aspiration, aspiration pneumonia (w/wo demonstrable pharyngeal dysmotility) XI.h XI - Miscellaneous
XI.h - Esophageal pathology (erosion, ulcer, tear, rupture, fistula) XI.i XI - Miscellaneous
XI.i - Esophageal toxicity XI.p XI - Miscellaneous
XI.p - Chest deformity: platythorax XI.v XI - Miscellaneous
XI.v - Rib fracture XI.ag XI - Miscellaneous
XI.ag - Vertebral compression fracture XI.ax XI - Miscellaneous
XI.ax - Esophageal stenosis/stricture XI.bb XI - Miscellaneous
XI.bb - Aorto-esophageal fistula XI.bs XI - Miscellaneous
XI.bs - Dropped-head syndrome XII.a XII - Cardiovascular involvement / toxicity
XII.a - Left or biventricular dysfunction/failure XII.b XII - Cardiovascular involvement / toxicity
XII.b - Valvular heart disease and/or dysfunction XII.f XII - Cardiovascular involvement / toxicity
XII.f - Cardiomyopathy (acute, subacute, chronic) XII.g XII - Cardiovascular involvement / toxicity
XII.g - Coronary artery disease (acute) - Myocardial ischemia/infarction XII.k XII - Cardiovascular involvement / toxicity
XII.k - Constrictive pericarditis - Pericardial thickening XII.o XII - Cardiovascular involvement / toxicity
XII.o - Coronary artery disease (subacute, chronic) XII.s XII - Cardiovascular involvement / toxicity
XII.s - Heart block (bundle branch- or AV-) XII.ad XII - Cardiovascular involvement / toxicity
XII.ad - Effusive-constrictive pericarditis XII.ak XII - Cardiovascular involvement / toxicity
XII.ak - Late left ventricular dysfunction/failure XII.an XII - Cardiovascular involvement / toxicity
XII.an - Pericardial calcification XII.bc XII - Cardiovascular involvement / toxicity
XII.bc - Coarctation of the aorta (acquired) XIII.a XIII - Neoplastic conditions
XIII.a - Lung cancer XIII.d XIII - Neoplastic conditions
XIII.d - Malignant mesothelioma (pleural, pericardial) XIII.e XIII - Neoplastic conditions
XIII.e - Breast cancer XIII.j XIII - Neoplastic conditions
XIII.j - Pulmonary synovial sarcoma XIII.l XIII - Neoplastic conditions
XIII.l - Chondrosarcoma XIII.m XIII - Neoplastic conditions
XIII.m - Tumor of the heart XV.f XV - Pathology
XV.f - Path: Diffuse alveolar damage (DAD-pattern) (see also IL) XV.l XV - Pathology
XV.l - Path: Pulmonary fibrosis (not otherwise specified or unclassifiable) XVI.ab XVI - Imaging
XVI.ab - Imaging: Cavitating/cavitary lung nodule, mass or nodules (see also Iq, XIs, XIIi, XVIaa and XVIIp) XVI.bi XVI - Imaging
XVI.bi - Imaging: Hyperlucent lung XVI.bj XVI - Imaging
XVI.bj - Imaging: Atelectasis (a combination of increased density and volume loss. Typically lobar)
3

Radiation therapy to the breast

I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD) I.c I - Interstitial/parenchymal lung disease
I.c - Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia) I.d I - Interstitial/parenchymal lung disease
I.d - Organizing pneumonia pattern (an area or areas of consolidation on imaging) I.h I - Interstitial/parenchymal lung disease
I.h - Subclinical pulmonary infiltrates/ILD I.o I - Interstitial/parenchymal lung disease
I.o - Focal/localized area of pneumonitis/fibrosis I.u I - Interstitial/parenchymal lung disease
I.u - Relapsing or migrating pneumonitis/pneumonia (see also Id) I.v I - Interstitial/parenchymal lung disease
I.v - Abnormal lung function/pulmonary physiology (PFTs) without necessarily imaging or clinical evidence I.z I - Interstitial/parenchymal lung disease
I.z - An area or areas of consolidation V.t V - Pleural and/or pericardial involvement
V.t - The apical cap XII.b XII - Cardiovascular involvement / toxicity
XII.b - Valvular heart disease and/or dysfunction XII.c XII - Cardiovascular involvement / toxicity
XII.c - Pericardial effusion (w/wo tamponade) XII.o XII - Cardiovascular involvement / toxicity
XII.o - Coronary artery disease (subacute, chronic) XIII.a XIII - Neoplastic conditions
XIII.a - Lung cancer XIII.m XIII - Neoplastic conditions
XIII.m - Tumor of the heart XV.c XV - Pathology
XV.c - Path: Organizing pneumonia (OP/BOOP) pattern (see also Id) XVI.i XVI - Imaging
XVI.i - Imaging: An area or areas of involvement with a recognizable anatomic distribution XIX.a XIX - Cytological, biochemical features of/in BAL, pleural fluid or FNA
XIX.a - BAL: An excess proportion of lymphocytes
2

Radiation therapy to the chest

I.a I - Interstitial/parenchymal lung disease
I.a - Pneumonitis (ILD), acute and/or severe (may cause ARDS) I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD) I.c I - Interstitial/parenchymal lung disease
I.c - Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia) I.d I - Interstitial/parenchymal lung disease
I.d - Organizing pneumonia pattern (an area or areas of consolidation on imaging) I.g I - Interstitial/parenchymal lung disease
I.g - Pulmonary fibrosis I.h I - Interstitial/parenchymal lung disease
I.h - Subclinical pulmonary infiltrates/ILD I.k I - Interstitial/parenchymal lung disease
I.k - Lung nodule or nodules I.l I - Interstitial/parenchymal lung disease
I.l - Diffuse alveolar damage (DAD) (see alsoo under IIb and XVf) I.o I - Interstitial/parenchymal lung disease
I.o - Focal/localized area of pneumonitis/fibrosis I.v I - Interstitial/parenchymal lung disease
I.v - Abnormal lung function/pulmonary physiology (PFTs) without necessarily imaging or clinical evidence I.x I - Interstitial/parenchymal lung disease
I.x - Pleuroparenchymal fibroelastosis (PPFE) I.y I - Interstitial/parenchymal lung disease
I.y - Progression, acceleration or exacerbation of preexisting ILD/fibrosis II.b II - Pulmonary edema - Acute lung injury - ARDS
II.b - ARDS - Acute lung injury III.h III - Pulmonary/alveolar./airway hemorrhage/bleeding
III.h - Major/massive hemoptysis IV.h IV - Airway involvement
IV.h - Large airway necrosis IV.m IV - Airway involvement
IV.m - Bronchial stenosis/stricture V.a V - Pleural and/or pericardial involvement
V.a - Pleural effusion (uni- or bilateral) (can accompany DI-LDs) V.c V - Pleural and/or pericardial involvement
V.c - Pleural thickening V.f V - Pleural and/or pericardial involvement
V.f - Pneumothorax V.h V - Pleural and/or pericardial involvement
V.h - Chylothorax V.k V - Pleural and/or pericardial involvement
V.k - Pleural calcifications VI.c VI - Pulmonary vasculopathies
VI.c - Pulmonary veno-occlusive disease VI.x VI - Pulmonary vasculopathies
VI.x - Pulmonary lymphangiectasis VII.d VII - Mediastinal involvement
VII.d - Fibrosing mediastinitis VIII.c VIII - Central-large-upper airway (incl. pharyngeal-nasal) involvement
VIII.c - Upper airway obstruction other than angioedema or hematoma VIII.r VIII - Central-large-upper airway (incl. pharyngeal-nasal) involvement
VIII.r - Tracheal/large airway necrosis, chondronecrosis, perforation VIII.t VIII - Central-large-upper airway (incl. pharyngeal-nasal) involvement
VIII.t - Vocal cord paresis/paralysis VIII.ab VIII - Central-large-upper airway (incl. pharyngeal-nasal) involvement
VIII.ab - Airway (e.g. tracheoesophageal) fistula IX.j IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.j - Phrenic nerve injury - Hemi- or bilateral diaphragmatic paralysis XI.b XI - Miscellaneous
XI.b - Chest pain (acute or subacute), lone or prominent XI.h XI - Miscellaneous
XI.h - Esophageal pathology (erosion, ulcer, tear, rupture, fistula) XI.i XI - Miscellaneous
XI.i - Esophageal toxicity XI.j XI - Miscellaneous
XI.j - Esophageal dysmotility XI.w XI - Miscellaneous
XI.w - Cavitation/necrosis of lung tumor or metastases XI.ag XI - Miscellaneous
XI.ag - Vertebral compression fracture XII.b XII - Cardiovascular involvement / toxicity
XII.b - Valvular heart disease and/or dysfunction XII.k XII - Cardiovascular involvement / toxicity
XII.k - Constrictive pericarditis - Pericardial thickening XII.o XII - Cardiovascular involvement / toxicity
XII.o - Coronary artery disease (subacute, chronic) XII.s XII - Cardiovascular involvement / toxicity
XII.s - Heart block (bundle branch- or AV-) XIII.e XIII - Neoplastic conditions
XIII.e - Breast cancer XV.c XV - Pathology
XV.c - Path: Organizing pneumonia (OP/BOOP) pattern (see also Id) XV.f XV - Pathology
XV.f - Path: Diffuse alveolar damage (DAD-pattern) (see also IL) XV.h XV - Pathology
XV.h - Path: NSIP-fibrotic pattern XV.i XV - Pathology
XV.i - Path: Pneumocyte atypia (reactive epithelial cells) (a.k.a. the "Napoleon Hat" sign) XV.bm XV - Pathology
XV.bm - Path: Diffuse lymphangiectasis XVI.bl XVI - Imaging
XVI.bl - Imaging: An area or areas of avid tracer uptake in the lung/chest on 18F-PET scan XVII.e XVII - Infections & related conditions
XVII.e - Pneumocystis jiroveci pneumonia XVII.af XVII - Infections & related conditions
XVII.af - Reactivation of a prior pulmonary infection (TB, melioidosis) XIX.a XIX - Cytological, biochemical features of/in BAL, pleural fluid or FNA
XIX.a - BAL: An excess proportion of lymphocytes
3

Radiation therapy, mantle-field-

2

Radiocontrast media (RCM)

I.c I - Interstitial/parenchymal lung disease
I.c - Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia) I.j I - Interstitial/parenchymal lung disease
I.j - Exogenous lipoid pneumonia (subacute, acute) I.v I - Interstitial/parenchymal lung disease
I.v - Abnormal lung function/pulmonary physiology (PFTs) without necessarily imaging or clinical evidence II.a II - Pulmonary edema - Acute lung injury - ARDS
II.a - Pulmonary edema, noncardiogenic (NCPE) II.b II - Pulmonary edema - Acute lung injury - ARDS
II.b - ARDS - Acute lung injury II.h II - Pulmonary edema - Acute lung injury - ARDS
II.h - Overload pulmonary edema (including posttransfusional (TACO)) II.i II - Pulmonary edema - Acute lung injury - ARDS
II.i - Flash (fulminate) pulmonary edema III.a III - Pulmonary/alveolar./airway hemorrhage/bleeding
III.a - Alveolar hemorrhage (AH), diffuse AH (DAH) IV.a IV - Airway involvement
IV.a - Bronchospasm - Wheezing - Asthma IV.b IV - Airway involvement
IV.b - Bronchospasm and angioedema IV.f IV - Airway involvement
IV.f - Severe or catastrophic bronchospasm or asthma attack (can be fatal) VI.e VI - Pulmonary vasculopathies
VI.e - Fat/oil embolism - The FES embolism syndrome VI.aa VI - Pulmonary vasculopathies
VI.aa - Lipiodol pulmonary embolism X.f X - Systemic/Distant conditions, syndromes and reactions
X.f - Anaphylaxis-Anaphylactoid reaction (can be fatal) X.g X - Systemic/Distant conditions, syndromes and reactions
X.g - Hypersensitivity reaction (may manifest with fever and/or skin, throat or airway involvement) X.n X - Systemic/Distant conditions, syndromes and reactions
X.n - Tumor lysis syndrome (TLS) X.ap X - Systemic/Distant conditions, syndromes and reactions
X.ap - Delayed anaphylaxis XVIII.h XVIII - Distinctive patterns - 'Eye-catchers'
XVIII.h - Eye-catcher: Lipiodol embolism
1

The Pneumotox website uses cookies. By accessing or using our website, you consent to the collection, use and disclosure of the garnered information in accordance with our privacy policy.

Learn more about cookies